The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 150.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.667%)
Open: 155.00
High: 155.00
Low: 155.00
Prev. Close: 155.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Mar 2017 10:54

RNS Number : 7446Y
Faron Pharmaceuticals Oy
07 March 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Faron Pharmaceuticals Oy

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Yes

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

 

Legal & General Group Plc (L&G)

 

Legal & General (Unit Trust Managers) Limited (UTM)

 

4. Full name of shareholder(s)  (if different from 3.):

 

N/A

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

03 March 2017

6. Date on which issuer notified:

07 March 2017

7. Threshold(s) that is/are crossed orreached:

 

UTM (Below 5%)

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD NPV

1,365,000.00

 Below 5%

-

 Below 5%

-

 Below 5%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

 

 

 

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

 UTM

(Below 5%)

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( 1,565,000 - 5.64%= Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 1,565,000 - 5.64%= Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 1,565,000 - 5.64%= Total Position)

Legal & General (Unit Trust Managers) Limited (Below 5% = UTM)

Legal & General Group Plc (Direct) (L&G) ( Below 3% = LGAS, & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH) (LGAS)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

 

 

 

 

13. Additional information:

Notification using the total voting rights figure of  27,734,044

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLKMGGFGNMGNZM
Date   Source Headline
19th Jul 20237:01 amRNSFaron to Hold BEXMAB Study Conference Call
19th Jul 20237:00 amRNSBEXMAB study update
30th Jun 20234:52 pmRNSHolding(s) in Company
29th Jun 20237:00 amRNSAnnouncement of Placing
12th Jun 20237:00 amRNSExercise of options
9th Jun 20238:00 amRNSNew biomarker data from BEXMAB study at EHA2023
5th Jun 20237:00 amRNSBoard Member to Assume Transactional Advisor Role
24th Apr 20237:00 amRNSBexmarilimab Efficacy and Safety in MATINS Trial
19th Apr 20237:00 amRNSBexmarilimab KOL Event
18th Apr 20237:00 amRNSPoster Presentations at AACR 2023
17th Apr 20237:00 amRNSBEXMAB study update
13th Apr 20234:30 pmRNSFaron at Canaccord Oncology Virtual Conference
29th Mar 20237:00 amRNSAppointment of Chief Financial Officer
24th Mar 20231:35 pmRNSBoard Change
24th Mar 20231:30 pmRNSResults of AGM
22nd Mar 20237:00 amRNSPositive FDA Feedback to Progress Bexmarilimab
3rd Mar 20239:00 amRNSNotice of Faron Pharmaceuticals Ltd’s AGM
3rd Mar 20237:15 amRNSFaron´s Annual Report 2022 Published
3rd Mar 20237:00 amRNSFinancial Statement January 1 to December 31 2022
6th Feb 20236:00 pmRNSUpdate to Faron’s Financial Calendar for 2023
6th Feb 20237:00 amRNSNotice of 2022 Full-Year Results and Annual Report
1st Feb 20233:45 pmRNSHolding(s) in Company
27th Jan 20235:45 pmRNSHolding(s) in Company
27th Jan 20237:00 amRNSResults of Placing
26th Jan 20234:30 pmRNSProposed Issue and Placing
16th Jan 202311:00 amRNSPrice Monitoring Extension
16th Jan 20239:05 amRNSSecond Price Monitoring Extn
16th Jan 20239:00 amRNSPrice Monitoring Extension
16th Jan 20237:00 amRNSTitle: BEXMAB study update
23rd Dec 20227:00 amRNSFaron’s Financial Calendar for 2023
5th Dec 20227:00 amRNSBEXMAB Study Update
1st Dec 20227:00 amRNSFaron Appoints Maija Hollmén PhD as CSO
18th Nov 20224:30 pmRNSAmendment Terms and Conditions with IPF Partners
2nd Nov 20227:00 amRNSFaron Announces Poster Presentation at SITC
31st Oct 20227:00 amRNSBEXMAB Study Update
19th Oct 20229:20 amRNSHolding(s) in Company
18th Oct 202212:30 pmRNSHolding(s) in Company
18th Oct 20227:00 amRNSFaron Announces Melanoma Cohort Data from MATINS
14th Oct 20227:00 amRNSResults of Placing
13th Oct 20225:31 pmRNSProposed Issue and Placing of Shares
22nd Sep 20227:00 amRNSGrant of Options
20th Sep 20227:00 amRNSTop-Line Data on Bexmarilimab Dose Variation
14th Sep 20227:00 amRNSFaron to Host Bexmarilimab Update Webcast
13th Sep 20227:00 amRNSTraumakine Data Presented at MHSR Symposium
7th Sep 20221:00 pmRNSFaron to Present at Upcoming Conferences
25th Aug 20227:00 amRNSFaron Reports 2022 Half-Year Financial Results
8th Aug 20227:00 amRNSNotice of Half-Year Financial Results
7th Jul 20229:45 amRNSResults of EGM
30th Jun 20225:00 pmRNSHolding(s) in Company
28th Jun 20221:47 pmRNSRegistration of New Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.